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Abstract
The Centers for Disease Control and Prevention have demonstrated continuous increased risk for 
maternal mortality and severe morbidity with racial disparities among non-Hispanic black women 
an important contributing factor. More than 50,000 women experienced severe maternal morbidity 
in 2014, with a mortality rate of 18.0 per 100,000, higher than in many other developed countries. 
In 2012, the first “Putting the ‘M’ back in Maternal-Fetal Medicine” session was held at the 
Society for Maternal-Fetal Medicine’s (SMFM) Annual Meeting. With the realization that rising 
risk for severe maternal morbidity and mortality required action, the “M in MFM” meeting 
identified the following urgent needs: (i) to enhance education and training in maternal care for 
maternal-fetal medicine (MFM) fellows; (ii) to improve the medical care and management of 
pregnant women across the country; and (iii) to address critical research gaps in maternal 
medicine. Since that first meeting, a broad collaborative effort has made a number of major steps 
forward, including the proliferation of maternal mortality review committees, advances in 
research, increasing educational focus on maternal critical care, and development of 
comprehensive clinical strategies to reduce maternal risk. Five years later, the 2017 M in MFM 
meeting served as a “report card” looking back at progress made but also looking forward to what 
needs to be done over the next 5 years, given that too many mothers still experience preventable 
harm and adverse outcomes.
Keywords
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Increasing severe maternal morbidity and mortality in the United States are well 
characterized. The Centers for Disease Control and Prevention have demonstrated 
continuous increases in maternal risk over recent decades,1–3 with racial disparities among 
non-Hispanic black women an important contributing factor.4–6 More than 50,000 women 
experienced severe maternal morbidity in 2014, with a mortality rate of 18.0 per 100,000.7,8 
Maternal risk for a range of complications including postpartum hemorrhage, severe 
preeclampsia, cardiovascular and noncardiovascular medical conditions, and peripartum 
hysterectomy has been stable or increased.1,6,9–12 In 2012, the first “Putting the ‘M’ back in 
Maternal-Fetal Medicine” session was held at the Society for Maternal-Fetal Medicine’s 
(SMFM) Annual Meeting. With the realization that rising risk for severe maternal morbidity 
and mortality2,13–15 required action, the “M in MFM” meeting identified the following 
urgent needs: (i) to enhance education and training in maternal care for maternal-fetal 
medicine (MFM) fellows; (ii) to improve medical care and management of pregnant women; 
and (iii) to address critical research gaps in maternal medicine.16 Five years later, the 2017 
M in MFM meeting served as a “report card,” looking back at progress made and also 
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looking forward to what needs to be done over the next 5 years, given that too many mothers 
still experience preventable harm and adverse outcomes. ’
Progress on M in MFM initiatives has occurred within a broad collaborative effort dedicated 
to improving maternal care that includes the American Congress of Obstetricians and 
Gynecologists (ACOG), the American Board of Obstetrics and Gynecology (ABOG), 
SMFM, the National Partnership for Maternal Safety (NPMS) under the Council on Patient 
Safety in Women’s Health Care, the Centers for Disease Control and Prevention (CDC), the 
Eunice Kennedy Shriver National Institute of Child Health and Human Development 
(NICHD), the Alliance for Innovation on Maternal Health, and other organizations. Leaders 
in these organizations participated in the creation of this “report card.” In addition to 
reviewing progress on the original recommendations from “Putting the ‘M’ back in 
maternal-fetal medicine,”16 this report card also focuses on an important new development: 
stepwise and coordinated progress toward improving maternal death reviews nationwide in 
the United States. Systematic maternal death reviews have been an invaluable resource in 
understanding risk and improving maternal safety in the United Kingdom;15 a similar 
approach in United States will be critical in improving care.
Education
Five major educational recommendations were developed from the 2012 M in MFM 
meeting: (i) MFM fellows should complete mandatory rotations on labor and delivery 
(L&D) and in an intensive care unit (ICU); (ii) MFM fellowships should use simulations and 
case-based learning to enhance education in maternal medicine; (iii) MFM should have 
active certification in advanced cardiac life support (ACLS); (iv) MFM fellows should 
undergo a yearly in-service examination similar to that administered to residents by the 
Council on Resident Education in Obstetrics and Gynecology; (v) MFM fellows should 
receive training in leadership skills via formal leadership courses as well as participation in 
hospital-level quality assurance committees and quality initiative projects.
Completed
Mandatory L&D and ICU training—Prior to the initial M in MFM meeting, fellowship 
requirements were 12 months of clinical rotations without a requirement for L&D or ICU 
rotations. ABOG has subsequently modified the MFM fellowship to include 15 months of 
clinical rotations including 2 months of L&D/inpatient services and a 1-month ICU rotation.
16
 Per communication with ABOG, prior to this change, the L&D training among fellowship 
programs varied in structure, education, supervision, timing, and duration. In some 
programs, the L&D experience was unstructured and service-oriented, consisting simply of 
night and weekend call. All programs had to develop structured rotations with newly defined 
educational L&D objectives and advanced responsibilities for fellows. There has been a 
subsequent increase in interest in maternal care, with 11 MFM physicians now certified in 
critical care. Many centers are pursuing the addition of a critical care fellowship as an 
adjunct to maternal-fetal medicine training. For the M in MFM meeting, 1 year of MFM 
thesis data were reviewed: approximately 45% of MFM fellowship theses are on maternal 
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health topics. Per communication with ABOG, going forward data on MFM theses will be 
tracked.
Simulation and case-based learning—Given that maternal deaths occur rarely and 
many life-threatening maternal conditions are low prevalence, simulation and case-based 
learning represent an important means of preparing MFM providers to manage life-
threatening severe morbidity scenarios.17–19 Obstetric simulation training may result in 
improved interdisciplinary teamwork and better patient outcomes with fewer medical and 
communication errors.20 Simulation for maternal cardiac arrest has resulted in improved 
knowledge, confidence, and competence in management of this life-threatening clinical 
scenario.21,22 The annual Critical Care in Obstetrics—An Innovative and Integrated Model 
for Learning the Essentials course is held separately from SMFM’s annual conference. 
ABOG was intimately involved in creation of this multi-day training course; ABOG worked 
to identify the 20 most important topics in maternal medicine and critical care obstetrics to 
reduce maternal morbidity and mortality. Since 2014, a total of 1791 obstetrician-
gynecologists have taken the course. The program includes online lectures, case studies, 
simulation sessions, as well as a 3-day onsite course with in-person simulation, virtual 
reality, and skill development focused on developing obstetric critical care skills. Resident 
attendance at the Annual Critical Care in Obstetrics course is particularly important in 
maternal care education, given that the majority of obstetric providers in the United States 
are not MFM specialists.
In-service examinations—After careful review, it was determined by ABOG that, given 
the sample of test takers, the development of in-service examinations was not 
psychometrically feasible for MFM fellows.
Active ACLS certification—Because many obstetrics and gynecology residencies require 
ACLS training, MFM fellows often arrive at fellowship with this certification. Many 
programs now require maintenance of certification during fellowship.
Expanded leadership training—To address leadership gaps in MFM, over the last 5 
years the Society for Maternal-Fetal Medicine has sponsored the SMFM Academy for 
Leadership and Development. Two 3-day on-site courses in Denver, Colorado, with 
additional facilitated dialogues during the 6 interceding months focus on leadership 
imperatives including strength-based leadership, crucial conversations and accountability, 
and change management. This important skill development helps to focus efforts in leading 
change, especially as it relates to reducing maternal morbidly and mortality. Maternal care 
improvements require MFM-led implementation of hospital-level care initiatives, inter-
hospital collaboration, and communication with hospital and hospital system leadership; 
leadership training was a gap identified by SMFM members.
Clinical
The original M in MFM meeting developed 5 specific recommendations for improving 
maternal clinical care on a national basis: (i) development of a national, stratified system for 
levels of maternal care with high-risk patients triaged to centers with appropriate resources 
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and expertise; (ii) creation of guidelines and bundles to prevent and to manage the leading 
causes of severe maternal morbidity and mortality; (iii) increasing departmental and 
divisional support for MFM subspecialists focusing on maternal care, including facilitating 
academic advancement for MFM inpatient directorships; (iv) improving maternal care 
reimbursement and billing coding for maternal care; and (v) creating models for 
comprehensive care for mothers at high risk secondary to acute or chronic comorbid 
conditions.
Completed
Levels of maternal care—The Obstetric Care Consensus on Levels of Maternal Care, 
developed by ACOG and SMFM, provides uniform designations for levels of maternal care, 
standardized definitions, quality guidelines, and nomenclature for each level of maternal 
care, and recommendations for equitable geographic distribution of full-service maternal 
care facilities and systems to improve maternal safety and outcomes across the United 
States. For each level of care, the document makes recommendations for staffing, center 
capabilities, and where patients with specific risk factors should deliver.23 The Obstetric 
Care Consensus document is supported and endorsed by leading anesthesia, pediatric, and 
nursing societies.
In progress
Guidelines and bundles—The National Partnership for Maternal Safety under the 
Council on Patient Safety in Women’s Health Care, representing all major women’s 
healthcare professional organizations, has published bundles on obstetric hemorrhage, severe 
hypertension, thromboembolism, and racial and ethnic disparities, leading causes of severe 
maternal morbidity and mortality.24–27 These bundles represent a selection of existing 
guidelines and recommendations in a form that aids implementation and consistency of 
practice for individual centers, with the goal of improving prevention, recognition, and 
management of life-threatening medical and obstetric conditions. Examples of care 
improvement supported by these bundles include optimizing thromboembolism prophylaxis, 
improving recognition and management of obstetric hemorrhage, and timely treatment of 
severe hypertension. In addition, ACOG and SMFM have created specific management 
recommendations for high-risk conditions such as placenta accrete,28 and SMFM has 
focused on the role of reducing disparities in improving overall maternal outcomes.29,30 
Facilitating statewide bundle implementation is 1 of the priorities of the Alliance for 
Innovation on Maternal Health (AIM) that has partnered with professional societies, 
industry, and governmental organizations to improve maternal care. The Safe Motherhood 
Initiative in New York State has facilitated statewide implementation of thromboembolism, 
obstetric hemorrhage, and hypertension bundles.31 Implementation of the hemorrhage 
bundle has led to decreased risk for severe morbidity in California.32 Adoption of parallel 
recommendations for management of hypertension has led to decreased risk for eclampsia 
and severe morbidity.33
Quality assessment of severe maternal morbidity.: Transfusion of 4 or more units of 
blood products, admission to an intensive care unit, or both were developed at the M in 
MFM meeting as simple measures of severe maternal morbidity to prompt case reviews 
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within all hospitals that deliver obstetric care.34 To aid in guidance of severe maternal 
morbidity case reviews, recommendations have been developed for a standardized 
interdisciplinary approach to identifying systems and professional and facility factors with 
the goal of improving hospital-level safety. Included are recommendations on committee 
organization, the review process, medical record abstraction and assessment, review culture, 
data management, review timing, and review confidentiality. An accompanying structured 
severe maternal morbidity abstraction and assessment form to aid in morbidity reviews is 
available for download at: http://safehealthcareforeverywoman.org/.35,36 Uniform diagnostic 
criteria for amniotic fluid embolism have been developed to aid in diagnosis of this 
condition.37 Similar to what is done by our colleagues in neonatology, severe morbidity 
should be tracked on large-scale, systematic bases by state and regional maternal quality 
care collaboratives.
Career support and academic advancement for maternal-care—focused MFM 
subspecialists.: Supporting maternal care—focused MFM subspecialists is a substantial 
challenge, despite clear clinical needs. Although states with a high density of MFM 
specialists generally have lower mortality rates, several states with high MFM density have 
high mortality rates, suggesting that some MFM specialists may not be providing maternal-
focused care.38 A significant proportion of generalist obstetricians express dissatisfaction in 
the availability and/or the limited scope of practice of MFM specialists. Data from a recent 
MFM workforce survey found that only 47.5% of MFMs working full-time take in-house 
call in hospitals providing higher-acuity maternal care (Level III or IV centers).39 
Encouraging and supporting MFM specialists who focus on maternal care will continue to 
be an urgent priority, given national needs.
Improving reimbursement for maternal care.: Coding courses have shown great benefit 
in obtaining improved reimbursement for maternal care. Providers and billing staff may 
attend SMFM coding courses specifically for MFM coders and physicians. Departmental 
leadership may encourage providers and billing staff to attend these courses and billing staff 
to optimize coding for maternal reimbursement.
Models of comprehensive maternal care.: Comprehensive maternal care centers, modeled 
on prenatal diagnosis/fetal referral centers (Level IV Regional Perinatal Health Care 
Centers) are evolving. As an example, the Mothers Center at Columbia University serves as 
a quaternary referral center for maternal high-risk diagnoses such as maternal cardiac 
disease, placenta accreta, and other major medical, surgical, and obstetric conditions. Care is 
coordinated with maternal-care—focused MFM providers and medical and surgical 
subspecialists with expertise in obstetric patients in the same clinical space; in this model, 
the quaternary maternal center can serve as a resource to both community providers and 
other academic centers.
Emerging concepts.: Innovation in healthcare delivery will play an essential role in 
reducing maternal risk, as patient needs are often not one-size-fits-all. For example, 
compared to presenting for office blood pressure checks, patient engagement of outpatient 
follow-up for hypertensive diseases of pregnancy may be improved by remote patient 
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monitoring that allows patients to monitor blood pressure at home, to have their 
measurements digitally logged through a tablet, and then to have providers automatically 
notified of abnormal parameters. Given that cardiac and noncardiac medical conditions are 
now the leading causes of maternal death, use of innovative technological interventions to 
improve patient engagement and to monitor high-risk conditions may represent opportunities 
to reduce major sources of maternal risk.40 Aligning with initiatives to improve engagement 
with women in the postpartum period, remote patient monitoring along with structured 
“virtual visits” may represent a means of improving care for both high-risk and low-risk 
patients.
Critical Research Gaps
The 2012 M in MFM meeting identified 7 critical research gaps related to maternal care 
including the following: (i) the need for a standardized definition of significant maternal 
morbidity and “near misses”; (ii) the need for risk prediction models for severe morbidity 
and mortality, including maternal early warning systems to avert adverse outcomes; (iii) 
guidance on delivery timing to optimize maternal and neonatal outcomes, including 
management of placenta accrete; (iv) economic analyses demonstrating cost savings 
associated with improved maternal care; (v) research on effectiveness of maternal care 
training and education; (vi) research on long-term outcomes after an adverse pregnancy; and, 
as discussed in the section below, (vii) national surveillance of maternal mortality and 
morbidity. Addressing these knowledge gaps is a top priority of the NICHD.
Research supported by the NICHD
The Eunice Kennedy Shriver National Institute of Child Health and Human Development 
(NICHD) supports a broad range of maternal health research. Recent key topics in this area 
have included advanced maternal age as it relates to maternal risk, health services, and 
systems of care in obstetrics, maternal comorbidities, depression, preeclampsia and 
hypertension, HIV, labor and delivery complications, obstetrics pharmacology, 
environmental exposures, gestational diabetes, obesity, and placental complications. From 
2011 to 2016, maternal-focused NICHD research has increased from approximately $129 
million to $138 million annually. At the request of the NICHD, the National Institutes of 
Health (NIH) agreed to add a maternal health category to NIH-wide reporting which 
commenced in 2017. This new category was designed to enable better tracking of “maternal 
health” research at the National Institutes of Health.
Of the 7 critical research gaps in maternal health identified in 2013, NICHD has supported 
work to address each of these areas, with examples for each highlighted in Supplementary 
Table 1. In addition to specific researcher-initiated grants, NICHD supports major initiatives 
and programs such as the National Survey of Family Growth, the Population Dynamics 
Research Infrastructure Program, the Maternal-Fetal Medicine Units Network, the Global 
Network for Women’s and Children’s Health, the Obstetric-Fetal Pharmacology Units 
Network, and the Consortium on Safe Labor.37,41–60
To simplify data sharing with the research community, NICHD has developed and launched 
the Data and Specimen Hub (DASH; https://dash.nichd.nih.gov/). This is a centralized 
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resource for researchers to store and access data from NICHD-funded research studies to use 
for secondary analyses. In addition, NICHD supports the Biospecimen Repository Access 
and Data Sharing (BRADS) site, a repository of epidemiologic studies and clinical trials 
(https://brads.nichd.nih.gov/).
National Surveillance
The CDC’s Pregnancy Mortality Surveillance System (PMSS) has been tracking maternal 
deaths in the United States since 1986. This system relies on death certificates for women 
thought to have died during or within 1 year of pregnancy, as well as linked birth and/or fetal 
death certificates shared voluntarily from the Divisions of Vital Statistics from the 50 states 
and the District of Columbia (https://www.cdc.gov/reproductivehealth/maternalinfanthealth/
pmss.html). When information on these records is viewed with a clinical eye, causes of 
death can be ascribed in a more nuanced fashion than when using conventional International 
Classification of Disease coding. However, information on death certificates is likely more 
accurate for certain types of deaths than others (eg, postpartum hemorrhage vs pre-existing 
chronic disease), and the quality of documentation may vary significantly by state (eg, 
availability of records linked to birth certificates). Both under-ascertainment and false-
positive results are a concern when surveillance is based solely on vital records.61,62 
Furthermore, the certificate itself can rarely provide any insight into the personal or medical 
circumstances surrounding the death. Hence, state and regional maternal mortality review 
(MMR) committees are likely able to provide more particulate and accurate data based on 
death identification from multiple sources, and these committees are well positioned to 
ascertain causality based on in-depth reviews of obstetric care and circumstances of death. If 
surveillance and review are done for the purpose of effecting change and preventing future 
events, it is the process information that must be understood to inform improvement. This 
information can be gleaned only from in-depth review. Although currently an aspirational 
idea, it is conceivable that systematic maternal death reviews on the state level across the 
United States could begin to approach the Confidential Enquiries into Maternal Deaths in 
the United Kingdom. As of 2013, a total of 18 states and 1 city had active MMR 
committees; as of today, the SMFM estimates that 36 states have MMR committees, with 9 
states planning or starting up committees.
In supporting federal legislation to advance the national proliferation of MMR committees, 
SMFM was a key partner in a coalition of national organizations including ACOG, the 
Association of Maternal and Child Health Programs, the March of Dimes, the Preeclampsia 
Foundation, and others that advocated successfully for Congress to double funding for the 
CDC’s efforts to support MMR committees. SMFM members participated in (i) grassroots 
efforts to encourage Congress for this support, and (ii) multiple direct education efforts with 
policymakers in the form of Congressional briefings, testimony, and hearings. HR 1318, the 
Preventing Maternal Deaths Act, a bill that SMFM endorsed, advocated for, and hosted, and 
for which the SMFM co-sponsored Congressional briefings and on which it submitted 
testimony to Congress, was signed into law in December 2018. This legislation authorizes 
the CDC to provide assistance to states in setting up MMR committees and ensuring 
standardized review and data collection processes. SMFM endorsed several state efforts to 
create new or improve established MMR committees, and many MFMs serve as chairs of 
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MMR committees in their states. In addition, the M in MFM initiative facilitated SMFM’s 
dialogue with the CDC to provide a role for SMFM in supporting MMR committees. In the 
new 2019 Congressional session, SMFM plans to support the reintroduction of other bills 
addressing disparities, expanding Medicaid for postpartum women, authorizing the AIM 
program (for which SMFM sits on the executive team), and providing support for perinatal 
quality collaboratives.
In addition to the formation of MMR committees in most states, the quality of reviews may 
be improving as well. Via the Alliance for Innovation on Maternal Health (AIM), 
approaches and “lessons learned” from mortality reviews may be broadly disseminated. The 
CDC is currently facilitating efforts on suggested data standards for reporting from 
individual MMR committees as well as providing expertise on maternal death data 
abstraction, informant interviews, and committee processes. The Association of Maternal 
Child Health Programs in partnership with the CDC Foundation and the CDC Division of 
Reproductive Health has recently developed a Web-based resource, Review to Action (http://
www.reviewtoaction.org/about-us). This effort aims to provide technical assistance to new 
review committees, to connect existing committees with new and veteran committees, and to 
raise awareness of the critical roles that such reviews can play in eliminating preventable 
deaths. The ultimate goal of improving maternal mortality surveillance in the United States 
is for every maternal death to undergo a high-quality death review.
Conclusion
Since the first “M in MFM” meeting 5 years ago, major educational, research, and clinical 
strides have been made to improve maternal safety by a broad collaborative effort. Critical 
care and labor floor rotations are now required during MFM fellowship training. Critical 
care teaching has been provided to more than 1700 obstetrician-gynecologists and maternal 
fetal medicine specialists. The NICHD has supported more than 0.5 billion dollars in 
maternal research. Academic, industry, state, and federal leadership have developed a 
number of major safety initiatives to improve maternal care.
To successfully reduce maternal mortality in the United States, these achievements will have 
to be sustained and built upon over the coming years. Models of maternal care will need to 
be developed to manage risk from cardiovascular and noncardiovascular medical conditions 
that are now the leading causes of maternal mortality. Although a number of major 
initiatives to improve maternal safety on the hospital level have been developed—from 
criteria and strategies for severe morbidity review to bundles for thromboembolism, 
hemorrhage, and hypertension—implementation across the more than 3000 hospitals in the 
United States that provide obstetric services—in short, developing national maternal safety 
standards—represents a formidable challenge.63 Supporting maternal-fetal medicine 
specialists focused on maternal safety in the setting of differential and unfavorable 
reimbursement relative to prenatal diagnosis and ultrasound necessitates commitment from 
departmental and hospital leadership. Creating a true national surveillance system that is 
able to critically evaluate safety gaps and to disseminate lessons learned and 
recommendations for care improvement will rely on states developing expertise in 
performing high-quality death reviews.
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